Alibaba bans online listing and trade of pharmaceutical products
Sweeping ban includes APIs, intermediates and prescription and OTC medicines and comes amid tight regulatory requirements and the "high risk nature" of pharma products, e-commerce giant says
Chinese e-commerce platform Alibaba has prohibited the listing and trading of pharmaceutical products, including active pharmaceutical ingredients (APIs), intermediates and prescription and over-the-counter medicines.
The sweeping ban came into effect on Wednesday, April 28, after initially being announced on April 20 with Alibaba saying that penalties will start to be imposed against any violations of the new rules.
The largely unexpected move will hand competitive advantage to regulated and specialized online operators such as Kemiex, Amazon Pharmacy and others in their respective fields.
“In light of the regulatory requirements and the high risk nature of pharmaceutical products, Alibaba.com has revised the ‘Rules of Prohibited and Restricted Products’ to assist members in complying with applicable laws and maintain the sustainable development of the platform,” the company said in a notice to clients.
As a result, Alibaba said it would be shutting down four sub-categories on its platform (Medicine, Pharmaceutical, Veterinary Medicine and Herbal Medicine) and products listed under these headings would be “taken down in batches” and banned from being sold under any other categories.
Pharma products subject to the ban also include human and animal drugs, hormonal drugs, steroids, radiopharmaceuticals, antibiotics, vaccines, traditional Chinese herbs and medicines and special pharmaceuticals such as analeptics and blood products.
“The aforementioned products are strictly prohibited by the platform, regardless of whether the seller, the buyer, the manufacturer or the product has relevant qualifications,” Alibaba said, adding that non-compliant products will be removed from listing or deleted.
“Kemiex remains the only regulated online platform to buy and sell pharmaceutical raw materials,” said Pau Franquet, chief executive officer at the online trade platform and data provider, adding that the company holds a Good Distribution Practice (GDP) certification from Swissmedic.
Seen as a worldwide pioneer, Switzerland strengthened its regulatory landscape and Therapeutic Products Act in 2019 in anticipation of a growing ecosystem of online solutions, as well as explicitly recognizing broker and agency activities.
The global online pharmacy market – which delivers finished prescription and OTC products – continues to grow due to increasing internet access and the popularity of smartphones, with dominant players including Amazon, Carepoint Healthcare and Giant Eagle.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance